Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lianghai Hu has a total of 258 co-authors. Here are the top co-authors by number of shared publications:

  • Muhammad Mujahid Ali

    Department of Chemistry, Purdue University, West Lafayette, IN 47907, USA

    11 shared publications
  • Xianhui Cheng

    School of Life Sciences, Jilin University, Changchun 130023, China

    11 shared publications
  • Juntao Zhou

    Center for Supramolecular Chemical Biology, State Key Laboratory of Supramolecular Structure and Materials, School of Life Sciences, Jilin University, Changchun 130023, China

    10 shared publications
  • Wenjing Yu

    Center for Supramolecular Chemical Biology, State Key Laboratory of Supramolecular Structure and Materials, School of Life Sciences, Jilin University, Changchun 130023, China

    10 shared publications
  • Mingliang Ye

    State Key Laboratory of Medical Proteomics, CAS Key Laboratory of Separation Sciences for Analytical Chemistry, National Chromatographic R&A Center, Dalian Institute of Chemical Physics, Chinese Academy of Sciences (CAS), Dalian, China

    9 shared publications
  • Shengnan Jia

    Department of Hepatopancreatobiliary Medicine, The Second Hospital, Jilin University, Changchun, China

    8 shared publications

Latest Publications

  • Dual-template molecular imprinting enables fully synthetic phosphatidylserine-targeted cancer therapy

    by Shuhan Hu, Wenjing Yu, Luxi Chen, Muhammad Mujahid Ali, Juntao Zhou, Lei Ye, Lianghai Hu

    This study develops a phosphatidylserine-targeting nanocarrier that enables precise drug delivery to triple-negative breast tumors, significantly inhibiting growth while minimizing systemic toxicity.

  • Dysprosium(III)–Nanopolymer Functionalized Array for Capture of Extracellular Vesicles and In Situ Phosphoprotein Analysis

    by Guangyao Wu, Aixiang Bu, Xin Feng, Zhichao Ren, Linlin Zeng, Hao Zhang, Lianghai Hu

    The analysis of extracellular vesicle (EV) phosphoproteins holds great promise for biomarker discovery but is hindered by the multi-step and inefficient nature of conventional methods. Here, we develop a novel dysprosium(III)–nanopolymer (PEI–Dy3+) functionalized array for the simultaneous capture and in situ (on-membrane capture, lysis, and detection without sample transfer) phosphoprotein analysis of EVs. This platform leverages the high affinity of Dy3+ for phosphate groups to enable an integrated workflow for EV capture and phosphoprotein enrichment on the array, followed by on-membrane detection. The array exhibited excellent analytical performance with high phosphopeptide specificity, uniform EV capture, and robust 15 day stability. Furthermore, it outperformed ultracentrifugation by achieving higher EV purity (76.3% vs 63.6% for UC and 68.0% for ADSP) and detecting more EV proteins (1296 vs 520 for UC). When applied to an Alzheimer’s disease (AD)-like damaged cell model, the array enabled LC–MS/MS-based quantification of 107 significantly altered phosphoproteins from Aβ25–35 stimulated SH-SY5Y cells culture medium, revealing disease-relevant pathways and kinase activities. Finally, the platform enabled in situ detection of AD-related EV phosphoproteins, including APP and SEPTIN2 in cell models, and further validated APP in a pilot clinical cohort of AD patients and healthy controls. Overall, the PEI–Dy3+ functionalized array facilitates the capture of EVs and subsequent in situ analysis of their phosphoproteins, thereby providing a novel and efficient analytical tool for EV phosphoprotein analysis.

  • Proteomic advances in extracellular vesicles: unlocking biomarkers for microbial infectious diseases

    by Yuxia Huang, Juntao Zhou, Chu Wang, Lianghai Hu

    1. Microbial infectious diseases remain a major threat to global public health. The emergence of highly fatal pneumonia caused by viruses and the increasing prevalence of multidrug-resistant bacter...

  • Selective Recognition of Tumor-Derived EVs by EpCAM-Imprinted Polymers for Proteomic Biomarker Discovery

    by Wenjing Yu, Fengxiang Lou, Luxi Chen, Shilong Zhao, Feng Wei, Lianghai Hu

    EpCAM, a key biomarker for epithelial tumors, is overexpressed in multiple cancers and enriched on tumor-derived extracellular vesicles (EVs), positioning it as a promising liquid biopsy target. However, conventional isolation methods such as ultracentrifugation suffer from nonspecific adsorption and interference from normal EVs, obscuring critical biological information. In this study, we developed a highly selective artificial antibody material based on molecular imprinting technology, using the N-terminal sequence of EpCAM as a template for targeted capture of EpCAM-positive (EpCAM+) EVs. The resulting molecularly imprinted polymer (MIP) exhibited an adsorption capacity of 11.76 × 103 μg/g and an imprinting factor of 6.02, demonstrating excellent template recognition. At the cellular level, MIP selectively bound to EpCAM-high tumor cells (e.g., PANC-1, HeLa) while showing negligible adsorption to normal cells (293T), confirming its targeting specificity. Proteomic analysis of preoperative versus postoperative urine samples and matched tumor versus peritumor tissues revealed that MIP-captured EVs reliably reflect tumor status, with tumor-associated proteins such as GPC1 and TIMP1 exhibiting consistent expression changes across both sample types. In summary, this study establishes a method for specific capture of EpCAM+ EVs in complex biological environments. The low cost and high stability of the MIP material offer a novel tool for liquid biopsy. With further validation using large-scale clinical samples, this approach may have potential for advancing EpCAM+ EV-based early diagnosis of malignant tumors such as pancreatic cancer (PC) and for enabling new strategies in tumor microenvironment research and personalized therapy.


  • Glycoproteomics of body fluids and derived exosomes in hepatocellular carcinoma

    by Dongna Xie, Shengnan Jia, Nian Wang, Lianghai Hu

  • Proteomics Study of Breast Cancer-Derived Small Extracellular Vesicles: Unveiling Potential Cancer Biomarkers

    by Cao Hoang Long Ngo, Su Su Thae Hnit, Wei Zhang, Xin Feng, Victoria Ie Ching Tan, Lianghai Hu, Simon Chang-Hao Tsao, Yuling Wang

    Small extracellular vesicles (sEVs) are lipid-bilayer-enclosed vesicles secreted by cells into the extracellular environment, carrying a variety of biomolecules, including proteins that reflect the molecular profile of their cell of origin. In particular, cancer-derived sEVs hold significant potential for cancer diagnosis due to their unique biomolecular content. In this study, we utilized mass spectrometry to profile the protein expression in plasma-derived sEVs from both healthy controls (HCs) and breast cancer (BC) patients with the aim of discovering new protein biomarkers for potential BC diagnosis. Through the cross-validation of differentially expressed proteins between the two independent cohorts, we identified nine proteins that were significantly upregulated in BC-derived sEVs. Further validation using online gene expression data sets, Western blot, and ELISA revealed that OIT3 was upregulated in BC tissue compared to HC tissue, suggesting its potential as a novel BC biomarker. These findings contribute to advancing the knowledge of proteins within sEVs, as well as offering promising avenues for the use of sEVs as biomarkers in future cancer diagnostic applications.


  • Open Access

    Molecular imprinting strategies and advances targeting biomembranes

    by Xueting Yuan, Liang Wang, Luxi Chen, Lianghai Hu

    Biomembranes are selective barriers and communication interfaces between intracellular and extracellular environments. They are crucial for signal transduction, energy transfer, and material exchange. Composed of lipids, proteins, glycans, and other components, biomembranes are central platforms for cell recognition and communication. Their specific recognition and binding abilities show great potential in early disease diagnosis, targeted drug delivery, environmental monitoring, and more. Molecularly imprinted polymer (MIP) has emerged as a robust tool for recognizing and binding biomolecules on biomembranes. This article summarizes recent technological advancements in MIP for biomembrane-associated lipids, proteins, and glycans. Lipids are a key part of biomembranes, crucial for maintaining membrane fluidity and stability. In lipid imprinting, lipid bilayers serve as templates. Functional monomers interact with lipid molecules and, upon polymerization, form a polymeric shell on the bilayer. Template removal leaves behind complementary binding sites. This strategy has been exploited to fabricate lipid-imprinted nanoparticles for drug delivery. These nanoparticles selectively recognize lipid components on cell membranes, thereby enabling targeted drug delivery. Proteins constitute another critical class of biomembrane components and execute diverse functions. Protein-imprinted MIPs selectively recognize membrane proteins such as cell-surface receptors, bacterial outer-membrane proteins, and viral capsid proteins. This enables precise identification and binding of specific proteins, which is useful in disease diagnosis and drug development. MIP can detect specific membrane protein biomarkers on cancer cells, allowing for early cancer detection and monitoring. Glycans also play a key role in biomembranes, particularly in cell recognition and immune responses. Carbohydrate-imprinted MIPs recognize specific glycan structures for use in disease diagnosis and therapy. Cancer cells have different glycan structures on their membranes compared to normal cells. These abnormal glycans serve as biomarkers for early cancer detection and monitoring. The article also emphasizes the potential of MIP in various applications. In disease diagnosis, MIP can develop biosensors for fast and accurate detection of disease biomarkers, enabling early treatment. In drug delivery, MIP can create targeted systems that deliver drugs directly to diseased cells, minimizing off-target effects and enhancing therapeutic efficacy. In cell imaging, MIP can specifically label cells or biomolecules, providing detailed images of cellular processes and aiding in understanding disease mechanisms. In biosensing, MIP can serve as efficient recognition elements to construct biosensors for detecting specific biomarkers in biological samples. The specific binding sites formed by molecular imprinting technology enable MIP-based biosensors to detect target molecules with high sensitivity and selectivity, providing a powerful tool for early disease diagnosis and real-time monitoring. However, the development of MIP still faces challenges, including complex synthetic procedures, incomplete template removal, limited scalability, and the need for performance optimization. The synthesis process is complex, requiring precise control of parameters like functional monomers, cross-linkers, and initiators. Incomplete template removal compromises binding affinity and selectivity. Scaling-up while maintaining batch-to-batch reproducibility is challenging, and the binding capacity, selectivity, and stability of MIPs must be optimized for each application. For glycan imprinting, monosaccharide templates have low specificity, glycan chain templates are difficult to synthesize and purify, and there is a lack of efficient O-glycan cleavage tools. To break through the bottleneck, the study improves template removal efficiency, synthetic optimization and structural controllability through controllable free radical/photo-initiated polymerization, magnetic material integration, microfluidics, artificial intelligence, machine learning and 3D printing; meanwhile, virtual templates, glycopeptide substitution templates, and solid-phase imprinting strategies are used to solve the scarcity of glycan templates. In addition, optimization of biocompatible materials, surface modification to reduce toxicity, and combination with computer simulation and automated preparation can accelerate clinical translation. In conclusion, MIP technology is highly promising for biomembrane research with broad applications in disease diagnosis, drug delivery, cell imaging, and extracellular vesicle enrichment. With continued development and optimization, MIP are expected to play an increasingly important role in biomedical and life sciences, offering more powerful tools and solutions for disease diagnosis, treatment, and monitoring.